| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 02/19/1998 | WO1998006439A1 Polyetherester copolymers as drug delivery matrices |
| 02/19/1998 | WO1998006438A2 Composition for pharmaceutical applications |
| 02/19/1998 | WO1998006437A2 Compositions and methods for polynucleotide delivery |
| 02/19/1998 | WO1998006436A2 Inhibiting undesirable taste in oral compositions |
| 02/19/1998 | WO1998006423A1 Composition comprising insulin and insulin-like growth factor-i (igf-i) |
| 02/19/1998 | WO1998006420A1 Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| 02/19/1998 | WO1998006418A1 Compositions of plant carbohydrates as dietary supplements |
| 02/19/1998 | WO1998006407A1 Anthelmintic formulations |
| 02/19/1998 | WO1998006406A1 Mannose-6-phosphate composition and its use in treating fibrotic disorders |
| 02/19/1998 | WO1998006387A2 Oral composition comprising 5-aminosalicylic acid |
| 02/19/1998 | WO1998006382A1 Granulates comprising a water soluble compound and cellulose |
| 02/19/1998 | WO1998006381A1 Preservative systems for pharmaceutical compositions containing cyclodextrins |
| 02/19/1998 | WO1998006266A1 Antiviral materials |
| 02/19/1998 | WO1998001124A3 Pharmaceutical preparation containing nimesulide for topical use |
| 02/19/1998 | WO1997048385A3 Controlled release tablet |
| 02/19/1998 | WO1997044356A3 Ret ligand (retl) for stimulating neural and renal growth |
| 02/19/1998 | CA2263411A1 Composition for pharmaceutical applications |
| 02/19/1998 | CA2262524A1 Gnrh-leukotoxin chimeras |
| 02/19/1998 | CA2234245A1 Tablet of isotope-labeled urea |
| 02/19/1998 | CA2213030A1 Polyurethane-based thickener compositions and their use for thickening aqueous compositions |
| 02/18/1998 | EP0824126A1 Preparation of carboxylic acid-containing polyether and biologically active substances derived thereof |
| 02/18/1998 | EP0824019A1 Enzyme containing oral compositions |
| 02/18/1998 | EP0823996A1 Anti-infective against STD relating, for example, to HIV, Chlamydia, gonococcus, treponema pallidum or herpes simplex and device used to preserve/mix principal ingredient and base of such anti-infective |
| 02/18/1998 | EP0823895A1 Fatty acid esters as bioactive compounds |
| 02/18/1998 | EP0823889A1 1,3-propane diol derivatives as bioactive compounds |
| 02/18/1998 | EP0770381B1 Support and composition containing it together with a stabilised cosmetic or dermatologic agent |
| 02/18/1998 | EP0695177B1 Active substance-containing plaster |
| 02/18/1998 | EP0609217B1 Dry starch-iodine pharmaceutical formulations |
| 02/18/1998 | CN1173817A Method, compsns and kits for increasing the oral bioavilability of pharmaceuticalagents |
| 02/18/1998 | CN1173500A PEG-interferon conjugates |
| 02/18/1998 | CN1173391A Desiccant, dehydration therewith, and dehydrated product obtainable thereby |
| 02/18/1998 | CN1173366A Hypoglycemic high calcium granule and its prodn. |
| 02/17/1998 | US5719265 Antitumor agents with improved water solubility and reduced toxicity |
| 02/17/1998 | US5719197 Drug delivery |
| 02/17/1998 | US5719131 Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
| 02/17/1998 | US5719122 Enhancing transdermal or transmucosal absorption by administering with a saturated polyglycolysed glyceride |
| 02/17/1998 | US5719044 Complexing |
| 02/17/1998 | US5718920 Ion exchanger overcoated with permselective membrane |
| 02/17/1998 | US5718915 Antiviral liposome having coupled target-binding moiety and hydrolytic enzyme |
| 02/17/1998 | US5718905 Stirring a liquid phase consisting of a solution of cyclodextrin modified by acyl groups in an organic solvent with a second liquid phase essentially consisting of water |
| 02/17/1998 | US5718904 Adjuvant consisting of squalene, glycerol, surfactant |
| 02/17/1998 | US5718892 Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| 02/17/1998 | CA2026516C Injectable preparations containing cephalosporin medicament |
| 02/15/1998 | CA2209540A1 Anti-infective against std relating, for example, to hiv, chlamydia, gonococcus, treponema pallidum or herpes simplex and device used to preserve/mix principal ingredient and baseof such anti-infective |
| 02/12/1998 | WO1998005787A1 A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| 02/12/1998 | WO1998005689A1 Polymers for delivering nitric oxide in vivo |
| 02/12/1998 | WO1998005688A1 Amylose products as matrix former for programmed release systems, process for preparing these amylose products, and process for making programmed release systems |
| 02/12/1998 | WO1998005684A2 Mhc binding peptide oligomers and methods of use |
| 02/12/1998 | WO1998005364A2 Improvements in or relating to contrast agents |
| 02/12/1998 | WO1998005363A2 Polypeptides having a single covalently bound n-terminal water-soluble polymer |
| 02/12/1998 | WO1998005362A2 Protein-containing polymer composition for oral administration |
| 02/12/1998 | WO1998005361A2 Long-acting drugs and pharmaceutical compositions comprising them |
| 02/12/1998 | WO1998005360A2 Use of (meth)acrylic acid copolymers to increase the permeability of mucous membranes |
| 02/12/1998 | WO1998005359A1 Carrier composition for influencing the tight junction permeability |
| 02/12/1998 | WO1998005358A1 Sustained release preparations for injection containing gabexate mesylate |
| 02/12/1998 | WO1998005344A1 Bacteriophage-mediated gene therapy |
| 02/12/1998 | WO1998005341A1 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus |
| 02/12/1998 | WO1998005314A1 Novel stable liquid paracetamol compositions, and method for preparing same |
| 02/12/1998 | WO1998005313A1 Composition comprising mupirocin and chlorhexidine |
| 02/12/1998 | WO1998005312A1 Pleasant-tasting aqueous liquid composition of a bitter-tasting drug |
| 02/12/1998 | WO1998005309A1 Cyclosporin formulation |
| 02/12/1998 | WO1998005305A1 Tablet dosage form of clavulanic acid and amoxycillin comprising a trehalose excipient |
| 02/12/1998 | WO1998005304A1 Biocompatible devices with foam scaffolds |
| 02/12/1998 | WO1998005303A1 Bioadhesive complexes of polycarbophil and azole antifungal or antiprotozoal drugs |
| 02/12/1998 | WO1998005302A1 Aerosol formulations |
| 02/12/1998 | WO1997045139A3 Il-12 as an adjuvant for bordetella pertussis vaccines |
| 02/12/1998 | CA2262994A1 Polypeptides having a single covalently bound n-terminal water-soluble polymer |
| 02/12/1998 | CA2262908A1 Contrast agents for ultrasound imaging of the liver |
| 02/12/1998 | CA2262430A1 Composition comprising mupirocin and chlorhexidine |
| 02/12/1998 | CA2262405A1 A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| 02/12/1998 | CA2261742A1 The use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus |
| 02/11/1998 | EP0823439A1 Improvements in or relating to agglomeration of starch |
| 02/11/1998 | EP0822942A1 Modified anti-icam-1 antibodies and their use in the treatment of inflammation |
| 02/11/1998 | EP0822833A1 Polysaccharide-bound nitric oxide-nucleophile adducts |
| 02/11/1998 | EP0822832A1 Cd45rb binding compounds for the prevention of transplant rejection |
| 02/11/1998 | EP0822822A1 Controlled release of miotic and mydriatic drugs in the anterior chamber |
| 02/11/1998 | EP0822821A1 Complexing urushiols |
| 02/11/1998 | EP0822819A1 Solvent detergent emulsions having antiviral activity |
| 02/11/1998 | EP0822808A2 Composite with sodium starch glycolate as a support material and products thereof |
| 02/11/1998 | EP0822807A2 Gel with increased oxygen content |
| 02/11/1998 | EP0714407B1 Composition and methods using nitroxides to avoid oxygen toxicity |
| 02/11/1998 | EP0688429B1 Macromolecular microparticles and methods of production |
| 02/11/1998 | EP0630263B1 Pharmaceutical composition having site-specific delivery |
| 02/11/1998 | CN1173184A Identitication, purification and uses of leczymes and carbohydrate ligands |
| 02/11/1998 | CN1173183A Conjugates of BDNF and NT-3 with a water-soluble polymer |
| 02/11/1998 | CN1173129A Anti-inflammatory eyecrops |
| 02/11/1998 | CN1173128A Polynucleotide compositions |
| 02/11/1998 | CN1172677A Fill material for soft gelatin pharmaceutical dosage form |
| 02/11/1998 | CN1172646A Fill material for soft gelatin pharmaceutical dosage form containing antiflatulent |
| 02/11/1998 | CN1172642A Multiphase soft gelatin dosage form |
| 02/11/1998 | CN1172591A Dietetic foods and pharmaceutical preparations inhibiting blood coagulation |
| 02/11/1998 | CN1037322C Beta-cyclodextrin used for preparing oral liquid |
| 02/10/1998 | US5717087 For molded parts, sheets, fibers, coatings, blends, laminates, matrices for delayed release of active materials, paper coatings |
| 02/10/1998 | US5717074 Macrophage-derived inflammatory mediator (MIP-2) |
| 02/10/1998 | US5716992 Topical applying to human skin |
| 02/10/1998 | US5716991 Pharmaceutical compositions comprising paracetamol and L-cysteine or a precursor thereof |
| 02/10/1998 | US5716990 Drug delivery systems |
| 02/10/1998 | US5716987 Topically or transdermally administering phenoxyacetic acid and/or its lower alkyl ester |
| 02/10/1998 | US5716981 A stent coated with paclitaxel, a taxan derivative and a polymeric carrier; medical equipment for deblocking |
| 02/10/1998 | US5716928 Use of essential oils to increase bioavailability of oral pharmaceutical compounds |